Company Overview and News

14
Bursa stays lower at mid-morning

2018-06-14 malaymail
KUALA LUMPUR, June 14 — Bursa Malaysia remained lower at mid-morning today with continuous selling activities in selected heavyweights.
0133 PBLOF 5225 SNHHF 1295 Q0F BSMAF IHHHF 1818

11
Bursa recovers most of losses at early end to trade

2018-06-14 malaymail
KUALA LUMPUR, June 14 — Bursa Malaysia ended the half-day trading on a weaker note ahead of a long weekend for Hari Raya Aidilfitri and also in line with regional markets after the US Federal Reserve raised interest rates by a quarter-percentage point.
0133 5225 YTLPF SNHHF 6742 Q0F BSMAF IHHHF 1818

11
Bursa Malaysia ends lower

2018-06-14 malaymail
KUALA LUMPUR, June 14 — Bursa Malaysia ended the half-day trading on a weaker note ahead of a long weekend for Hari Raya Aidilfitri and also in line with regional markets after the US Federal Reserve raised interest rates by a quarter-percentage point.
0133 5225 YTLPF SNHHF 6742 Q0F BSMAF IHHHF 1818

22
KLCI narrows loss, but remains in the red as Genting, CIMB weigh

2018-06-14 theedgemarkets
KUALA LUMPUR (June 14): The FBM KLCI narrowed its losses at market close today, but remained in the red in line with its regional peers, dragged by losses at Genting-related stocks and CIMB Group Holdings Bhd.
7251 MLYNF 5197 BATS 4162 GMALY 0133 1023 4715 PNAGF GEBHF HRGHY MLYBY SPMXF GMALF 5681 SNHHF 6432 5168 6033 CIMDF 5139 1155 PNADF SPMXY 0900 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...